The global acute myeloid leukaemia drugs market is estimated to grow at a significant CAGR during the forecast period. An increasing incidence and prevalence of acute myeloid leukaemia, advancement in pharmaceutics and molecular biology, and growing R&D investment from pharmaceutical companies are all key factors propelling market expansion. Genetic abnormalities, poor lifestyles, chronic exposure to harmful substances such as benzene, and radiation exposure are all factors in the increased prevalence of acute myeloid leukaemia therapies. Furthermore, the growing geriatric population and increasing unmet healthcare needs would further bolster market expansion.

Biopharmaceutical benefits over conventional medications, the rising ageing population, unhealthy lifestyles, a strong biopharmaceutical pipeline, and combination treatments to cure previously treatable diseases are all important growth drivers of the global acute myeloid leukaemia market. The global acute myeloid leukaemia drugs market is increasing, which raises cancer awareness. According to the World Health Organization, doing a risk-free cancer test, which identifies behaviours that contribute to cancer and measures to reduce the risk, can prevent one-third of all malignancies.

Cytarabine is a drug that is used to treat a variety of leukaemias, including acute and chronic myelogenic leukaemia. It also treats Hodgkin lymphoma, meningeal leukaemia, and other kinds of lymphoma (cancers found in the lining of the brain and spinal cord). Due to its efficiency in the treatment of acute myeloid leukaemia, cytarabine is often used during chemotherapy that is further boosting the growth of the market.

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Chemotherapy

    • Regions Covered 

o North America

o Europe

o Asia-Pacific

o Rest of the World

    • Competitive Landscape- Sanofi-Aventis (Genzyme Corporation)., Teva Pharmaceutical Cephalon Inc., Pfizer Inc., Bristol-Myers Squibb Company., Sunesis Pharmaceuticals Inc. and others.

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How players are addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Acute Myeloid Leukemia Drug Market by Segment

By Chemotherapy

    • Cytarabine

    • Anthracycline Drugs

    • Daunomycin

    • Idarubicin

    • Mitoxantrone

    • Alkylating Agents

    • Anti-metabolites

    • Tyrosine Kinase Inhibitors

    • Dasatinib (Sprycel)

    • Imatinib (Gleevec)

    • Hormonal Therapy

    • Other Chemotherapies

Global Acute Myeloid Leukemia Drug Market by Region

North America

    • United States 

    • Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• Japan

• India

• Rest of Asia-Pacific 

Rest of World

    • Latin America

    • Middle East & Africa